Oracle is doubling down on life sciences with a major upgrade to its AI data platform, now rebranded as Life Sciences Data Intelligence. Unveiled at the Oracle Health and Life Sciences Summit 2026 in Orlando, the enhanced platform combines a customer's own data with Oracle's real-world data repository to help pharmaceutical, medical device, and research organizations move faster from discovery to commercialization.

The platform's standout feature is its domain-trained AI agents, which allow researchers to run complex analyses, build patient cohorts, and automate research workflows using natural-language queries — no extensive coding needed. It also offers traceable reasoning and audit trails, addressing a key concern in AI adoption: trust and transparency.

Quick Facts:

• The platform includes access to 122+ million longitudinal health records
• AI agents support tasks like cohort discovery, clinical trial recruitment, site optimization, and health economics research
• The platform is cloud-native and designed to scale with evolving data volumes and AI use cases
• It integrates across Oracle's broader ecosystem, including OCI, Oracle Fusion Cloud, and Oracle Health solutions

Why it matters: Fragmented data and disconnected workflows are a persistent bottleneck in clinical research. By unifying real-world data with AI-driven analytics in one governed platform, Oracle is aiming to cut the time and complexity it takes to generate credible evidence — potentially accelerating how quickly new treatments reach patients.